Evaluation of interleukin 6 and interleukin 4 levels in the serum of type 1 diabetic patients

محتوى المقالة الرئيسي

naima hussin

الملخص

تلعب السيتوكينات أدوارًا حاسمة في تنظيم التفاعلات بين خلايا بيتا البنكرياسية والخلايا المناعية في تطور داء السكري من النوع الأول، وثبت أن السيتوكينات المؤيدة للالتهابات التي تُطلق أثناء المرض يمكن أن تزيد الحالة المرضية، بينما توفر السيتوكينات المضادة للالتهابات الحماية.


هدفت هذه الدراسة الى تقييم مستويات IL-6 وIL-4 في مصل الأطفال المصابين بداء السكري من النوع الأول ومقارنتهم بالأصحاء.


تم اختيار 70 طفلا مصاب بداء السكري النوع الاول، و33 طفل غير مصاب بالسكري، خلال الفترة الممتدة من سبتمبر الى ديسمبر 2024. تم قياس مستويات الإنترلوكين-6 والإنترلوكين-4 في الدم باستخدام اختبار الإليزا.


اظهرت النتائج  في هذه الدراسة ارتفاع متوسط تركيزIL-6  في المرضى  12.95±0.83  مقارنة بالأصحاء 2.62±0.33 بدلالة معنوية p=0.001  , وارتفاع متوسط تركيز4IL- في الاصحاء 41.77±13.34  مقارنة بالمرضى18.71±7.08  ولكن بدون فارق معنوي p=0.10 ، كما اظهرت الدراسة وجود فروق معنوية في تركيزات IL-6 و IL-4 لدى الاطفال المصابين بداء السكري- النوع الاول ومدة الاصابة , وكان هناك علاقة ايجابية بين تركيزIL-6 والسكر التراكمي وكتلة الجسم والسكر الصائم , كما انه لم توجد اختلافات كبيرة في مستويات IL-6 بين الذكور والاناث المصابين بالسكري.


الاستنتاج: تدعم الأدلة المستمدة من هذه الدراسة احتمال وجود حالة التهابية مزمنة لدى الاطفال المصابين بداء السكري من النوع الأول، كما يتضح من المستويات المرتفعة لـ IL-6 في المصل، وكلما ازدادت مدة الإصابة يصبح التأثير أكثر خطورة على المصابين والتي قد تؤدي الى اضطرابات الأوعية الدموية الدقيقة، ومشاكل في العيون وفي الكلى.

تفاصيل المقالة

كيفية الاقتباس
hussin, naima. (2026). Evaluation of interleukin 6 and interleukin 4 levels in the serum of type 1 diabetic patients. المجلة الليبية للعلوم الطبية والتطبيقية, 4(1), 70–80. https://doi.org/10.64943/ljmas.2026.04170
القسم
Articles

المراجع

-Chala, T & Ali, G. (2016) Recent advance in diabetes therapy: pancreatic beta cell regeneration approachesDiabetes Manag 6(6), 108–118 ISSN 1758-1907.

- American Diabetes Association.)2018(Economic costs of diabetes in the U.S. in 2017. Diabetes Care; 41:917–928. https://doi.org/10.2337/dci18-0007

-Lu, J., Liu, J., Li, L., Lan, Y., Liang, Y. (2020) Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets. Clin Transl Immunology. 16;9(3): e1122. https://doi.org 10.1002/cti2.1122.

-Vasegh, H and Jadali, Z. (2016) Th1/Th2 cytokines in Type 1 diabetes: Relation to duration ofdisease and gender, Indian J Endocrinol Metab, 20(3):312–316. https://doi.org/10.4103/2230-8210.180002

-D'Agostino, S., Valentini, G., & Dolci, M. (2024). Exploring Interleukin Levels in Type 1 Diabetes and Periodontitis: A Review with a Focus on Childhood. Children (Basel, Switzerland), 11(2), 238. https://doi.org/10.3390/children11020238.

-Polychronakos, C and Li, Q. (2011) Understanding type 1 diabetes through genetics: advances and prospects. Nat Rev Genet; 12: 781–792.https://doi.org/10.1038/nrg3069.

-EL- Mohamady ,I., Haron,M., Rashed,L., Halawa,E., Badawy,N., Sediek,H.(2009) Cytokines in Egyptian Children with Type 1 Diabetes, Med. J. Cairo Univ., Vol. 77, No. 4: 191-196. www.medicaljournalofcairouniversity.com

-Nuhiar, R.S., Salman,A.N., AL-Rekaby,H.R. (2018) Some cytokines Levels (TGFβ1, IL-4, IL-6, and IL-17) in sera Patients with Diabetes Mellitus Type1, Type 2 in Nassiriya city, Volume 6, Number 4,42-48. http://jsci.utq.edu.iq

-Op de Beeck, A., Eizirik ,D.L.(2016) Viral infections in type 1 diabetes mellitus—why the β cells. Nature Reviews Endocrinology. 2016 May;12[5]:263-73.

-He, S., Xie,P., Luo,D., Sun,C., Zhang,Y., and Liu,F.(2014). Role of immune dysfunction in pathogenesisof type 1diabetes mellitus in children. Asian Pacific Journal Of Tropical Medicine 823-826. https://doi.org/10.1016/S1995-7645(14)60144-9

-Shelbaya, S., Amer,H., Seddik,S., Allah,A., Sabry,I., Mohamed,T., EL mosely,M. (2012) Study of the role of Interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients, European Review for Medical and Pharmacological Sciences, ; 16: 176-182

-Chen, Y.L., Qiao, Y.C., Pan, Y.H et al. (2017) Correlation between serum interleukin‐6 level and type 1 diabetes mellitus: a systematic review and meta‐analysis. Cytokine; 94: 14–20. https://doi.org/10.1016/j.cyto.2017.01.002

-Akdis, M., Burgler, S., Crameri, R., Eiwegger, T., Fujita, H., Gomez, E., Klunker,S., Meyer, N., Mahony, L., Palomares, O., Rhyner, C., Quaked, N., Schaffartzik, A., Veen, W., Zeller, S., Zimmermann, M. and Akdis, C(2011). Interleukins, from 1 to 37, and interferon-g: Receptors, functions, and roles in diseases. J. Allergy Clinc. Immunol. 127:701-721. https://doi:10.1016/j.jaci.2010.11.050. e1-70.

-Tayrab, E.M., Mahmoud, G.M., Abdelrahim H, M., Ahmed S., Elmakki A. (2021) Association of interleukin-4polymorphism with diabeticretinopathy and neuropathy in aSudanese population. Bulletin of the National Research Centre (45) 98. https://doi.org/10.1186/s42269-021-00555-5

-LaPorte, S.L., Juo, Z.S., Vaclavikova, J et al. (2008) Molecular and structural basis of cytokine receptorpleiotropy in the Interleukin-4/13 system. Cell132:259–272. https://doi.org/10.1016/j.cell.2007.12.030

-Seder, R.A., Paul, W. E., Davis, M.M., Fazekas,d.S., Groth, B. (1992) The presence of interleukin4 During in vitro priming determines the lymphokine-producing potential of CD4+ T cells from Tcell receptor transgenic mice. J Exp Med.176 (4).1091-8. https://doi.org/10.1084/jem.176.4.1091.

-Mi,Q.S.,Ly, D., Zucker, P.,McGarry, M. and Delovitch, T, L. (2004) Interleukin-4 but not Interleukin- 10 Protects Against Spontaneous and Recurrent Type 1 Diabetes by Activated CD1d-Restricted Invariant Natural Killer T-Cells. Diabetes May; 53(5): 1303-1310. https://doi.org/10.2337/diabetes.53.5.1303

-Targher, G., Zenati, L., Bertolini, L., Muggeo,M., Zoppini,G.(2001) Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care ;24(5):956–957. https://doi.org/10.2337/diacare.24.5.956

-Geerlings, S.E., Brouwer, E.C., Van Kessel, K.C., Gaastra, W., Stolk, R.P., Hopeman ,A.I. (2000) Cytokine secretion is impaired in women with diabetes mellitus. European Journal of Clinical Investigation ;30(11):995–1001. https://doi.org/10.1046/j.1365-2362.2000.00745.x

-Kikodze, N., Pantsulaia, I., Rekhviashvili, K., Iobadze, M. and JAkhutashvili, N. (2014) Cytokines and T regulatory cell in the pathogenesis of type1 diabetes. Georgian Med. News J. 222:29-35.

-Jasem, M. A. (2013) Autoantibodies and cytokines levels in type1 diabetes patients. Iraqi Postgrad. Med. J. 12(3):351-358.

-Pérez, F., Oyarzún, A., Carrasco, E., Angel, B., Albala, C., & Santos, J. L. (2004). Niveles plasmáticos de citoquinas IL-1beta, IL2 e IL-4 en niños diabéticos tipo 1 de diagnóstico reciente y su asociación con anticuerpos beta pancreáticos [Plasma levels of interleukin-1beta, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with beta-pancreatic autoantibodies]. Revista medica de Chile, 132(4), 413–420. https://doi.org/10.4067/s0034-98872004000400002

-Khaja, A. S. S., Binsaleh, N. K., Beg, M. M. A., Ashfaq, F., Khan, I., Almutairi, M. G., Qanash ,(2024) Clinical importance of cytokine (IL6, IL-8, and IL-10) and vitamin D levels among patients with Type-1 diabetes, Scientific Reports,14(1) https:// doi:10.1038/s41598-024-73737-6.

-Wilkin, T. J. (2013) Is autoimmunity or insulin resistance the primary driver of type 1 diabetes?Current Diabetes Reports;13(5):651–656. https:// doi: 10.1007/s11892-013-0407-7.

-Timar, R., Timar, B., Degeratu, D., Serafinceanu, C., Oancea, C. (2014) Metabolic syndrome, adiponectinand proinflammatory status in patients with type 1 diabetes mellitus. Journal of InternationalMedical Research.;42(5):1131–1138. https://doi.org/10.1177/0300060514541829.

-Siewko, K., Maciulewski, R., Zielinska-Maciulewska, A., Poplawska-Kita, A., Szumowski, P., Wawrusiewicz-Kurylonek, N., Lipinska, D., Milewski, R., Gorska, M., Kretowski, A., & Szelachowska, M. (2019). Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development. BioMed research international, 2019, 4734063. https://doi.org/10.1155/2019/4734063

-Zorena, K., Mysliwska,J., Mysliwiec,M., Balcersak,A., Lipowski,P., Raczynska,K. (2007) Relationship between serum levels of tumor necrosis factor-alpha and interleukin-6 in diabetes mellitus type 1 children, Central European Journal of Immunology 32(3):124-128.

-Hammed, I.K.,Rashid , N.F., Abed,B.A. (2012) Serum Interleukin-6 level in children with type 1 diabetes mellitus, J Fac Med Baghdad, Vol.54, No.3,228-230. https://www.researchgate.net/publication/325807718

-Alexandraki, K. I., Piperi, C., Ziakas, P. D., et al. (2008) Cytokine secretion in long-standing diabetesmellitus type 1 and 2: associations with low-grade systemic inflammation. Journal of ClinicalImmunology;28(4):314–321. https://doi.org/10.1007/s10875-007-9164-1

-Ryden, A., Faresjö,M.(2013) Altered immune profile from pre-diabetes to manifestation of type 1diabetes. Diabetes Research and Clinical Practice ;100 (1) :74–84. https://doi:10.1016/j.diabres.2013.01.014

-Kulseng, B., Skjak-Braek,G., Folling, I., Espevik ,T. (1996) TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide. Scandinavian Journal of Immunology;43(3):335–340. https://doi.org/10.1046/j.1365-3083.1996.d01-43.x

-Dogan, Y., Akarsu, S., Ustundag, B., Yilmaz, E., & Gurgoze, M. K. (2006) Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators of inflammation, 2006(1), 59206. https://doi.org/10.1155/MI/2006/59206

-Erbagci, A., Tarakcioglu, M., Coskun, Y., Sivasli ,E., and Namiduru, E. (2001) Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children.

Clinical Biochemistry. 34(8):645–650. https://doi.org/10.1016/s0009-9120(01)00275-2

-Abed Nasser,A. (2016) Immunological and genetic study of type I diabetes mellitus in a sample of Iraqi patients, A thesis, College of Education for Pure Science Al-Anbar University.

-Russell, M.A., Morgan, N.G. (2014) The impact of anti‐inflammatory cytokines on the pancreatic β‐cell. Islets; 6: e950547. https://doi.org/10.4161/19382014.2014.950547

-Khalaf, S.A., AL-Tameemi,H.K., Al-Dulimi,A.G., Hasan,W.Y. (2025) Elevated Serum Cytokines as Biomarkers for Type 1 Diabetes Mellitus in Diyala Province, Alqalam Journal of Medical and Applied Sciences, 8[1]:148-153. https://doi.org/10.54361/ajmas.258123

-Shaker, S.F., Khaleel,Y.K., Khalaf,S.D. (2025) Immune markers, biochemical parameters and genotoxicity in children infected with diabetes mellitus - type 1, International Journal of Fauna and Biological Studies; 12(2): 49-53. DOI: https://doi.org10.22271/23940522.2025.v12.i2a.1084

-Berwary, N. J., Majid, F., Hamdan, S., Khangholi, S. and Waheda, N. (2013) Viruses induce Type I diabetes mellitus in the presence of HLADR3, DR4 genes. J. Sci. Res. 18(7):916-925. https://DOI: 10.5829/idosi.mejsr.2013.18.7.1179.

-Novak, J., Beaudoin, L., Park, S., Griseri, T., Teyton, L., Bendelac, A. and Lehuen, A. (2007) Prevention of Type 1 diabetes by invariant NKT Cells is independent of peripheral CD1d expression. Immunology J. 178:1332-1340. https://doi.org/10.4049/jimmunol.178.3.1332

-Kent, S.C., Chen, Y., Clemmings, S.M et al. (2005) Loss of IL‐4 secretion from human type 1a diabeticpancreatic draining lymph node NKT cells. J Immunol; 175: 4458–4464.

-Kukreja, A., Cost, G., Marker, J et al. (2002) Multiple immuno‐regulatory defects in type‐1 diabetes. JClin Invest; 109: 131–140. https://doi.org/10.1172/JCI13605

-Kavitha, G.,Ramani,G., Dhass,P.K., Aruna,R.M.(2011) Oxidative stress,interleukin -6 and atherogenic index of plasma in diabetic nephropathy.International journal of applied biology and Pharmecutical technology; Volume: 2: Issue-2:211-217.

-Park, H., Park, J., Yu, R. (2005) Relationship of obesity and visceral adiposity with serumconcentrations of CRP, TNF-alpha and IL-6. Diabetes Research and Clinical Practice;69(1):29–35. https://doi.org/10.1016/j.diabres.2004.11.007.

-Trujillo, ME., Sullivan, S., Harten, I. (2004) Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab; 89:5577–5582. https://doi.org/10.1210/jc.2004-0603